Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHeiq Regulatory News (HEIQ)

Share Price Information for Heiq (HEIQ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.20
Bid: 8.90
Ask: 9.20
Change: -0.23 (-2.48%)
Spread: 0.30 (3.371%)
Open: 9.00
High: 9.20
Low: 9.00
Prev. Close: 9.28
HEIQ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Accounts Update

29 Sep 2023 07:00

RNS Number : 0824O
HeiQ PLC
29 September 2023
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation (2014/596) which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time.

 

29 September 2023

HeiQ Plc

("HeiQ" or the "Company" or the "Group")

Accounts update

Further to its AGM Statement announced on 29 June 2023, the Company provides the following update on the progress of its audited accounts for the year ended 31 December 2022 ("2022 Accounts") alongside an update on current trading for the six months ended 30 June 2023.

Accounts update

The Company is concluding its annual report and audit in conjunction with its auditor, Deloitte LLP and expects to publish its Full Year 2022 Accounts shortly, together with its interim results, following which the Company expects trading in its shares to recommence.

Following the completion of several acquisitions, the Group has grown significantly in terms of capabilities and technology platforms but also in terms of organizational complexity. The Company has seen a number of businesses with different systems, processes and cultures join the Group since 2017 and, in particular, during 2021. To integrate the different businesses, the Group commenced the harmonization of processes, systems, and operating practices across the organization in 2022. While this is a challenging project for any organization, the significant changes in market conditions in the year have made this process more onerous. All of these factors contributed to a significantly extended year end reporting timetable for 2022, with a related impact on the timing of the external audit work.

 

Previous announcements detailed the challenging market conditions that HeiQ has been enduring, which have impacted top line performance and Group profitability. Whilst management considers the Company to be performing better than many of its peers, the significant disruption in market demand across HeiQ's value chains has impacted the Company's financial performance for FY2022. HeiQ expects to report FY2022 revenue in line with the most recently published guidance but gross profit and loss from operations for FY 2022 are expected to be materially below previous market guidance as the significant drop in market demand has required HeiQ to review aspects of the accounting processes which rely on significant judgement. Key factors impacting profitability are set out below:

 

· Goodwill from acquisitions: The challenging market dynamics impaired the ability of its recently acquired businesses to achieve their initial business plans. Reviewing key judgements inherent in the Company's impairment review, including operating margins and long-term growth rates, has caused significant goodwill impairments in the period.

· Inventory valuation: Judgements surrounding allowances required for inventory have also been reassessed to reflect management's updated views on recoverability and caused the recording of significant allowances on inventory.

 

Furthermore, in the process of reviewing significant judgements with the auditors also for the prior year, the Company has had to record prior year restatements. Specifically, restatements have been recorded around impairment of goodwill from acquisitions as well as in relation to the accounting treatment of a significant take-or-pay contract. This contract has been renegotiated in 2023 and accounts receivable have been waived in exchange for a right of first refusal on the supply of a wide product range to a large industry player. While the Group is confident that the amendment to this contract will be beneficial going forward, the historical accounting treatment of this contract has been reviewed and it was determined that a restatement of prior year reported revenue and profits is appropriate, as recognition criteria had not been met.

 

 

The cash balance as of 31 December 2022 was US$8.5 million, in line with market guidance. To manage its cash balance, the Group has access to credit facilities totalling CHF9 million (approximately US$9.8 million). The facilities are in place with two different banks and both contracts have materially the same conditions. The facilities are not limited in time, can be terminated by either party at any time and allow overdrafts and fixed cash advances with a duration of up to twelve months. In case one or the other party terminates the agreement, fixed cash advances become due upon their defined maturity date. While the facilities are not committed, the Board has not received any indication from financing partners that the facilities are at risk of being terminated. Nevertheless, the Board acknowledges the uncommitted status of the facilities which could be terminated requiring the refinancing of debts, and which casts material uncertainty on the going concern assessment. The Board therefore expects the auditor to make reference to this material uncertainty in their audit opinion. The Board is in discussions with financial institutions to replace the currently uncommitted credit facilities by committed, long-term facilities, but the outcome of these discussions remain uncertain.

 

As at June 30, 2023, the Company had cash balances amounting to US$7.3 million with a total of CHF6.3 million drawn under the facilities.

 

Current trading and outlook

Since the start of FY 2023, HeiQ has focused on reducing its cost base and reorganizing the business, and the Company is pleased to report that it is already seeing the benefits of this. Whilst the Board has not yet seen the challenges abate in H1 2023, the action taken since the start of the year means the Company is expected to be in a better position in H2 2023 to manage the ongoing challenging macro-economic environment, continue building value in core innovations and preserve the Company's ability to deliver when the market demand turns.

 

For H1 2023, the Company expects to report sales of US$21 million (H1 2022: US$30 million) and a decrease in margins in a buyers-market, driven by current overcapacity. For H2 2023, the Company expects a stabilization of the financial performance and operating cashflows based on implemented cost measures becoming effective.

 

The Board believes that the medium and long-term opportunities for the Company's technology offering remain strong and the leadership team is focused on gaining market share for the commercialized core businesses, while also prioritizing innovation projects which have near-term market potential or significant long-term value creation potential. Each of HeiQ's key technology development projects has a significant market opportunity, and the Company's business infrastructure has been established to ensure effective rollout globally once market conditions change.

 

Further detail will be included in the Company's audited results for FY 2022 as well as its interim results. Financial reporting on H1 2023 performance will be published together with the Annual Accounts 2022.

PDMR Notifications

The Company also announces that, on 26 September 2022, options over 224,000 new ordinary shares in HeiQ ("Options") were made to each of Carlo Centonze and Xaver Hangartner pursuant to the Company's 2022 Option Plan. The Options have a strike price of 70.2p per share, being the trailing 5-day mid-market share price at the time of grant, a vesting period of three years and are subject to performance criteria as set out below.

•Vesting of 65% of the Options are conditional upon sales growth targets. Performance is measured over the years 2022-2024 and the performance target is 7.5% for each individual year or 24.2% compound sales growth over the three years 2022-2024.

•Vesting of 35% of the remaining Options are conditional upon annual operating margin targets. Performance is measured each year 2022-2024 and the performance target is 25%.

Further information is set out below pursuant to the requirements of the UK Market Abuse Regulation.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mr. Carlo Centonze

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

HeiQ plc

b)

LEI

213800IGT65IMJDO4S03

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Options over new ordinary shares of 30 pence each in the Company

 

GB00BN2CJ299

b)

 

Nature of the transaction

Grant of options pursuant to 2022 Company Share Option Plan

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

Exercise price of 70.2p per share

224,000

d)

 

Aggregated information

- Aggregated volume

- Price

N/A

 

e)

 

Date of the transaction

26 September 2022

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Xaver Hangartner

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

 

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

HeiQ plc

b)

LEI

213800IGT65IMJDO4S03

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Options over new ordinary shares of 30 pence each in the Company

 

GB00BN2CJ299

b)

 

Nature of the transaction

Grant of options pursuant to 2022 Company Share Option Plan

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

Exercise price of 70.2p per share

224,000

d)

 

Aggregated information

- Aggregated volume

- Price

N/A

 

e)

 

Date of the transaction

26 September 2022

f)

Place of the transaction

Outside a trading venue

 

 

 

 

For further information, please contact:

HeiQ Plc

Carlo Centonze (CEO)

+41 56 250 68 50

Cavendish Securities plc (Broker)

Stephen Keys / Callum Davidson

+44 (0) 207 397 8900

SEC Newgate (Media Enquiries)

Elisabeth Cowell / Molly Gretton / Tom Carnegie

+44 (0) 20 3757 6882

HeiQ@secnewgate.co.uk

 

About HeiQ

HeiQ is a Swiss-based international company that innovates pioneering and differentiating materials in partnership with established global brands. We bridge the academic and commercial worlds to conceive performance-enhancing materials and technologies, working with aligned brands to research, manufacture and bring products to market, aiming for lab to consumer in months. Our goal is to improve the lives of billions by innovating the materials that go into everyday products, making them more hygienic, comfortable, protective, and sustainable.

Our strong IP portfolio positions us as an innovation leader for niche, premium and high-margin products in the textile chemicals, man-made fibers, paints and coatings, antimicrobial plastics, probiotics and household cleaner markets. We have also expanded into healthcare facilities, probiotic cleaning, and hygiene coatings markets to help make hospitals and healthcare environments more hygienic.

We have developed over 200 technologies in partnership with 300 major brands. With a substantial research and development pipeline, including key technology development projects HeiQ AeoniQ, HeiQ ECOS, HeiQ GrapheneX, and HeiQ Synbio, HeiQ aims to deliver shareholder value through sales growth and entry into new lucrative markets through disruptive innovation and M&A.

We have built a strong reputation for ESG & sustainable innovation, having won multiple awards including the Swiss Technology Award twice and the Swiss Environmental Award. Under experienced leadership, we are committed to driving our profit in close connection with people and the planet. For more information, please visit www.heiq.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSEDESAEDSEFU
12
Date   Source Headline
22nd Apr 20247:00 amRNSHeiQ Synbio Secures Ecolab Contract Win
16th Apr 20242:17 pmRNSHolding(s) in Company
28th Mar 20247:00 amRNSUnaudited Interim Results
18th Mar 202412:41 pmRNSHolding(s) in Company
15th Mar 20247:00 amRNSHolding(s) in Company
14th Mar 20241:23 pmRNSCompletion of Fundraising, PDMR & Audit Update
13th Mar 20242:26 pmRNSResult of General Meeting
12th Mar 20247:00 amRNSBoard Changes
23rd Feb 20247:00 amRNSResult of Retail Offer
16th Feb 20247:00 amRNSResult of Placing
15th Feb 20245:49 pmRNSRetail Offer
15th Feb 20245:46 pmRNSAcquisition, Fundraising, Trading Update & GM
6th Dec 20232:46 pmRNSAgreed Changes to Concert Party
4th Dec 20237:00 amRNSDirector/PDMR Dealing
1st Dec 20233:04 pmRNSResult of General Meeting
30th Nov 20237:06 amRNSStatement Confirming Settlement
27th Nov 20237:00 amRNSBoard Appointment
8th Nov 20237:00 amRNSNotice of General Meeting
3rd Nov 20239:14 amRNSHolding(s) in Company
3rd Nov 20237:05 amRNSHolding(s) in Company
31st Oct 20237:43 amRNSFiling of Annual Report & Restoration of Trading
31st Oct 20237:30 amRNSRestoration - HEIQ PLC
30th Oct 20237:01 amRNSInterim Results
30th Oct 20237:00 amRNSResults for year ended 31 December 2022
23rd Oct 20237:00 amRNSNotice of Results and Audit Update
29th Sep 20237:00 amRNSAccounts Update
6th Jul 20237:00 amRNSMAS Holdings invests in HeiQ AeoniQ
29th Jun 20232:16 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
6th Jun 20237:00 amRNSNotice of AGM
2nd May 20237:44 amRNSTemporary Suspension of Trading in Ordinary Shares
27th Apr 20233:55 pmRNSTemporary Suspension
13th Jan 20232:09 pmRNSUpdate re. admission of Consideration Shares
12th Jan 20237:00 amRNSCompletion of Acquisition
10th Jan 20237:00 amRNSDirector / PDMR Dealing
6th Jan 20237:00 amRNSDirector / PDMR Dealing
5th Jan 20237:03 amRNSDirector/PDMR Shareholding
4th Jan 20237:00 amRNSTrading Update and Acquisition
14th Dec 20227:00 amRNSIncreased interest in HeiQ Chrisal to 71%
2nd Dec 20227:00 amRNSAcquisition of Chem-Tex Laboratories, Inc
7th Nov 20227:00 amRNSChange of Auditor
10th Oct 20227:00 amRNSFiles Breach of Exclusive Agreement Complaint
13th Sep 20227:00 amRNSInterim Results
30th Aug 20227:00 amRNSNotice of H1 2022 Results and Presentation
8th Aug 202210:33 amRNSIssue of Equity and Total Voting Rights
29th Jun 202211:06 amRNSResult of AGM
14th Jun 20227:00 amRNSCommercial progress of HeiQ’s Hygiene technologies
18th May 20227:00 amRNSNotice of AGM
12th May 20227:00 amRNSPayment of Earnout Consideration
28th Apr 20227:00 amRNSResults for the year ended 31 December 2021
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.